Agilon Health (AGL) Rallies On AI Care Narrative As Valuation Questions Linger
agilon health (AGL) has drawn fresh attention after its shares moved sharply over the past 3 months, prompting investors to reassess the company’s Medicare focused model and recent financial metrics.
See our latest analysis for agilon health.
The recent 7 day share price return of 11.2% and very large 90 day share price return, alongside a 1 year total shareholder return of 130.2% but a 3 year total shareholder return that declined 72.6%, suggest powerful short term momentum for agilon health after a difficult longer term period.
If agilon health’s surge has you rethinking your watchlist, this is a good moment to look across healthcare, including AI driven care models via the 40 healthcare AI stocks.
agilon health now trades far above the average analyst target, yet appears at a large discount to one estimate of intrinsic value. Is the market being cautious for good reason, or mispricing a sharp change in expectations?
Most Popular Narrative: 105.9% Overvalued
The most followed narrative currently anchors agilon health's fair value at $60.36, well below the recent $124.29 close. This sets up a clear tension between model assumptions and market pricing.
Strategic investments in advanced data analytics, AI-driven platforms, and enhanced burden-of-illness and quality assessment programs are improving the identification and management of high-risk patients, which should contribute to improved risk adjustment, better medical cost control, and higher net margins and earnings beginning in 2026.
Curious what earnings path and margin rebuild sit behind that fair value gap for agilon health? The narrative leans on measured revenue growth, a slim profit margin, and a valuation multiple usually linked with faster growing sectors. The interesting part is how those ingredients combine into a sharply lower fair value than today’s share price.
Result: Fair Value of $60.36 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, risks around payer concentration and leadership changes at agilon health, along with pressure on medical margins and risk adjustment revenue, could still challenge this upbeat narrative.
Find out about the key risks to this agilon health narrative.
Another View: agilon health on Sales Based Valuation
While the most popular narrative for agilon health focuses on a fair value of $60.36 and calls the stock overvalued, the current P/S ratio of 0.4x tells a different story. It sits below the peer average of 2.3x, the US Healthcare industry at 1.5x, and even a fair ratio of 0.5x, which points to a sizable valuation gap. Is that a margin of safety or a signal that earnings quality and volatility still carry real risk?
For a closer look at what the numbers imply if the market moves nearer to that fair ratio and peer levels, review the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
With sentiment on agilon health clearly mixed, it may be helpful to review the data, consider both sides, and see the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond agilon health?
If agilon health is on your radar, do not stop there. Broaden your opportunity set and pressure test your thesis with data driven stock ideas built from the same toolkit.
- Spot potential value opportunities early by reviewing the 47 high quality undervalued stocks before the rest of the market catches on.
- Prioritize resilience in tougher conditions by focusing on companies highlighted in the 78 resilient stocks with low risk scores.
- Target financial strength and staying power by scanning the solid balance sheet and fundamentals stocks screener (48 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com